Celldex Therapeutics has developed antibodies that target the human KIT antigen to treat KIT-associated disorders like rheumatoid arthritis and asthma. The method involves administering specific antibodies that inhibit KIT activity. This innovation opens new possibilities for managing various diseases and disorders. GlobalData’s report on Celldex Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Celldex Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Celldex Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Celldex Therapeutics's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for treating kit-associated disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Celldex Therapeutics Inc

A recently granted patent (Publication Number: US11891452B2) discloses a method for treating KIT-associated disorders such as rheumatoid arthritis, inflammatory bowel disease, asthma, allergic inflammation, gastrointestinal disorders, or mastocytosis. The method involves administering an isolated antibody or antigen-binding fragment that specifically binds to human KIT. The antibody comprises specific amino acid sequences in its light chain variable region (VL) and heavy chain variable region (VH), ensuring its immunospecificity to the target.

Furthermore, the patent claims encompass the administration of a second therapeutic agent in conjunction with the isolated antibody for enhanced treatment efficacy. The second therapeutic agent can be a chemotherapeutic agent, tyrosine kinase inhibitor, histone deacetylase inhibitor, antibody, or cytokine. Specific amino acid sequences are outlined for both the VL and VH regions of the antibody, allowing for variations in the composition while maintaining the desired therapeutic effect. Additionally, the patent covers the use of human IgG1 or IgG4 antibodies, monoclonal antibodies, bispecific antibodies, antibody fragments, and conjugates linked to agents for the treatment of KIT-associated disorders, particularly mastocytosis. This patent provides a detailed framework for utilizing immunospecific antibodies in the management and treatment of various KIT-associated disorders, offering potential advancements in therapeutic interventions for these conditions.

To know more about GlobalData’s detailed insights on Celldex Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies